Arthneeti
All Q1 FY26 results →
C

Cipla

Q1 FY26Pharmaceuticals & Biotechnology

Cipla Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹1,432
Market cap₹1.2L Cr
P/E32.3
Updated23 Aug 2026
Read4 min read

The short version

Cipla expects One India business to regain growth momentum and outperform the market in both branded prescription and trade generics segments, targeting growth in line with industry (around 8%-10%) for trade generics. - North America sales are expected to grow, with new product launches (including respiratory portfolio and Symbicort) to compensate for generic Revlimid loss, aiming for nearly $1 billion U.S. Cipla expects steady revenue growth with a strong focus on regaining growth momentum in India and expanding U.S.

From Cipla's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Cipla expects One India business to regain growth momentum and outperform the market in both branded prescription and trade generics segments, targeting growth in line with industry (around 8%-10%) for trade generics.
  • North America sales are expected to grow, with new product launches (including respiratory portfolio and Symbicort) to compensate for generic Revlimid loss, aiming for nearly $1 billion U.S. sales by FY '27.
  • Biosimilar pipeline to start product launches around '29-'30, with initial investments of $100 million over 3 years in partnerships and in-licensing.
  • One Africa business grew 11% YoY, with continued focus on expansion.

2 more points from Cipla's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Cipla said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Cipla is committed to investing $100 million in the biosimilars space over the next 3 years, with about 20-30% already spent since the commitment was made 3 years ago.
  • Focus of this investment is on in-licensing biosimilar products and building a biosimilar engine that mimics investment returns slightly higher than complex generics.
  • Own biosimilar products from Cipla's pipeline are expected to come to the market around 2029-2030, with current focus on partnership-based launches.
  • The company is enhancing commercial execution and accelerating new product introductions in North America.

2 more points from Cipla's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Cipla said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The provided transcript and pages from Cipla Limited's Q1 FY26 Earnings Call do not mention any information related to the current or expected order book or pending orders. Key points focus on: - Revenue performance, market growth, and product launches. - Discussions on biosimilars, generics, and US market strategies.

2 more points from Cipla's call on order book

Pro opens every point from 15K+ earnings calls

Cipla — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹6.5K Cr, net profit ₹543 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Cipla's management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Cipla and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Cipla Q1 FY26 results?

Cipla expects One India business to regain growth momentum and outperform the market in both branded prescription and trade generics segments, targeting growth in line with industry (around 8%-10%) for trade generics. - North America sales are expected to grow, with new product launches (including respiratory portfolio and Symbicort) to compensate for generic Revlimid loss, aiming for nearly $1 billion U.S. Cipla expects steady revenue growth with a strong focus on regaining growth momentum in India and expanding U.S.

What is Cipla share price analysis?

Cipla currently shows a neutral. The stock trades at a P/E of 32.3 with a market cap of ₹115,701 Cr. Investors should review the full earnings analysis for detailed insights.

Is Cipla planning capital expenditure?

Cipla is committed to investing $100 million in the biosimilars space over the next 3 years, with about 20-30% already spent since the commitment was made 3 years ago.

Keep Cipla on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.